Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12908884 | 0.94 | SCNN1A (0.46) | SCNN1A | |
| SCHEMBL12251710 | 0.88 | SCNN1A (0.58) | SCNN1A | |
| SCHEMBL19361224 | 0.87 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL16808735 | 0.86 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL2054438 | 0.86 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL13907673 | 0.86 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL9913772 | 0.85 | SCNN1A (0.64) | SCNN1A | |
| SCHEMBL9913763 | 0.85 | SCNN1A (0.53) | SCNN1A | |
| SCHEMBL12869105 | 0.85 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL10062650 | 0.85 | SCNN1A (0.67) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7820678-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100074881-A1 | MULTIPLE NEBULIZER SYSTEMS | PARION SCIENCES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090082287-A1 | METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES | PARION SCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| EP-1599096-B1 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7345044-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-7030117-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-7026325-B2 | Sodium channel blockers | PARION-SCIENCES, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060063780-A1 | Sodium channel blockers | JOHNSON MICHAEL R | 2006-03-23 | — | — | US | disclosed |
| US-6995160-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-6903105-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050113389-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113388-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113390-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20040162296-A1 | Sodium channel blockers | PARION SCIENCES, INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | SCNN1A 59/4885 |
| US-20090082287-A1 | METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES | SCNN1B, SLC10A2, SCNN1A | SCNN1A 3/4885 |
| US-20050113390-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20050113389-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20050113388-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20040162296-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20100074881-A1 | MULTIPLE NEBULIZER SYSTEMS | DNM2, MTNR1A, NBAS | SCNN1A 553/4885 |
| US-20060063780-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.